CAMBRIDGE, Mass. - VBI Vaccines Inc. (NASDAQ: NASDAQ:VBIV), a biopharmaceutical company, has announced that it will be delisted from the Nasdaq Stock Market effective August 8, 2024, following a notification received on July 30, 2024. This decision comes amidst the company's ongoing restructuring proceedings, which include a Chapter 15 filing in the U.S. and protection under the Canadian Companies' Creditors Arrangement Act (CCAA).
The U.S. Bankruptcy Court for the District of Delaware granted provisional relief under Chapter 15 on Thursday, with a further hearing scheduled to consider the recognition of the Initial Order from the Ontario Superior Court of Justice. The Initial Order, dated July 30, 2024, provided the company with CCAA protection.
Legal advisors for VBI during this process include Stikeman Elliott LLP, Haynes and Boone, LLP, Morris, Nicols, Arsht & Tunnell LLP, and Pearl Cohen Zedek Latzer Baratz. Ernst & Young Inc. (EY) has been appointed as Monitor in the CCAA proceedings and the proposed sale and investment solicitation process (SISP).
VBI Vaccines specializes in immunology and the development of vaccine candidates utilizing its proprietary virus-like particles (VLPs) technologies. The company is focused on addressing infectious diseases such as hepatitis B, coronaviruses, cytomegalovirus (CMV), and aggressive cancers like glioblastoma (GBM).
The company has stated that it does not intend to appeal the Nasdaq delisting determination. Additional information on the CCAA proceeding is available through the Monitor's website, and details on the Chapter 15 Case can be found via court documentation.
In other recent news, VBI Vaccines Inc. has secured an initial order from the Ontario Superior Court of Justice for creditor protection under the Companies' Creditors Arrangement Act (CCAA). The court protection includes a stay of proceedings, debtor-in-possession financing, and the appointment of Ernst & Young Inc. as the court's monitor during the restructuring process. The company also plans to initiate a case under Chapter 15 of the U.S. Bankruptcy Code and the Israeli Insolvency and Economic Rehabilitation Law to protect its subsidiaries and assets in Israel.
On the research front, VBI Vaccines Inc. has reported promising interim data from a Phase 2b study of their experimental cancer vaccine, VBI-1901. The vaccine, currently being tested on patients with recurrent glioblastoma (rGBM), showed a 43% disease control rate in the VBI-1901 study arm. Notably, seven patients treated with VBI-1901 displayed one partial tumor response and two stable disease observations, marked by a significant reduction in tumor size. The U.S. Food and Drug Administration (FDA) has granted VBI-1901 Fast Track and Orphan Drug Designations, which may expedite the drug development process. These are recent developments in the ongoing journey of VBI Vaccines Inc.
InvestingPro Insights
In light of VBI Vaccines Inc.'s recent announcement of its delisting from the Nasdaq and ongoing restructuring proceedings, InvestingPro provides real-time data and metrics that could be pivotal for investors monitoring the company's financial health and stock performance.
InvestingPro Data reveals that VBI Vaccines has a market capitalization of just $2.81 million, which is relatively small within the biopharmaceutical industry. This figure is indicative of the company's current valuation in the market. Additionally, the company's revenue has seen a significant increase, with a growth rate of 553.09% over the last twelve months as of Q1 2024, suggesting a substantial uptick in its business activities despite its operational challenges.
However, the financial metrics also highlight some concerns. The company's gross profit margin stands at -24.02%, reflecting costs that exceed revenues, which is a potential red flag for profitability issues. Moreover, VBI Vaccines has experienced a dramatic decline in its stock price, with a one-year total return of -90.94%, emphasizing the stock's poor performance and the impact of the challenges it faces.
InvestingPro Tips for VBI Vaccines underscore the significant debt burden and the company's rapid cash burn, which are critical considerations given its restructuring process. The stock's high volatility is another aspect for investors to watch closely. For those seeking further insights, InvestingPro offers additional tips, including the expectation of net income growth this year and the stock being in oversold territory according to the RSI, which could suggest potential for a rebound. There are 19 more InvestingPro Tips available that provide a comprehensive analysis of VBI Vaccines' financial and stock performance (https://www.investing.com/pro/VBIV).
Understanding these metrics and tips can offer investors a more nuanced view of the company's financial predicament and market sentiment, which is especially pertinent when navigating the uncertainties associated with restructuring and delisting proceedings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.